(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
1. A method of activating a cannabinoid receptor 2 in a human being experiencing pain, comprising administering to the human being an effective amount of a compound selected from the group consisting of
and a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is
3. The method of claim 1 , wherein the pain is acute pain.
4. The method of claim 2 , wherein the pain is acute pain.
5. The method of claim 3 , wherein the acute pain is trigeminal neuralgia.
6. The method of claim 4 , wherein the acute pain is trigeminal neuralgia.
7. The method of claim 1 , wherein the pain is visceral pain.
8. The method of claim 2 , wherein the pain is visceral pain.
9. The method of claim 1 , wherein the pain is neuropathic pain.
10. The method of claim 2 , wherein the pain is neuropathic pain.
11. The method of claim 9 , wherein the neuropathic pain is post-herpetic neuralgia.
12. The method of claim 10 , wherein the neuropathic pain is post-herpetic neuralgia.
13. The method of claim 9 , wherein the neuropathic pain is due to multiple sclerosis.
14. The method of claim 10 , wherein the neuropathic pain is due to multiple sclerosis.
15. The method of claim 9 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.
16. The method of claim 10 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.
17. The method of claim 1 , wherein the compound is administered in the form of a tablet, pill, or capsule.
18. The method of claim 2 , wherein the compound is administered in the form of a tablet, pill, or capsule.
19. The method of claim 3 , wherein the compound is administered in the form of a tablet, pill, or capsule.
20. The method of claim 9 , wherein the compound is administered in the form of a tablet, pill, or capsule.